Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Non-Current Assets (2020 - 2026)

Immuneering's Non-Current Assets history spans 7 years, with the latest figure at $53.4 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 328.06% to $53.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $133.4 million, a 155.11% increase, with the full-year FY2025 number at $55.7 million, up 324.62% from a year prior.
  • Non-Current Assets came in at $53.4 million for Q1 2026, down from $55.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $55.7 million in Q4 2025, with the low at $12.0 million in Q3 2025.
  • Historically, Non-Current Assets has averaged $18.0 million across 5 years, with a median of $13.4 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 702.36% in 2022 and later dropped 10.1% in 2025.
  • Year by year, Non-Current Assets stood at $13.6 million in 2022, then fell by 0.88% to $13.5 million in 2023, then dropped by 2.77% to $13.1 million in 2024, then surged by 324.62% to $55.7 million in 2025, then dropped by 4.2% to $53.4 million in 2026.
  • Business Quant data shows Non-Current Assets for IMRX at $53.4 million in Q1 2026, $55.7 million in Q4 2025, and $12.0 million in Q3 2025.